{"id":3534,"date":"2023-03-03T17:32:28","date_gmt":"2023-03-03T16:32:28","guid":{"rendered":"https:\/\/www.access2meds.eu\/consortium\/"},"modified":"2025-06-24T15:56:51","modified_gmt":"2025-06-24T13:56:51","slug":"consortium","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/fr\/consortium\/","title":{"rendered":"Consortium"},"content":{"rendered":"

[et_pb_section fb_built=\u00a0\u00bb1″ admin_label=\u00a0\u00bbHeader\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bb2e264158-b54d-4d7f-8146-8c8b7ca64cef\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1200929353_SolStock-e1679656039802.jpg\u00a0\u00bb background_position=\u00a0\u00bbtop_center\u00a0\u00bb background_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb background_image_phone=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Mobile-Header-2.png\u00a0\u00bb background_enable_image_phone=\u00a0\u00bbon\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_padding=\u00a0\u00bb7px|30px||30px|false|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_font=\u00a0\u00bb|700||on|||||\u00a0\u00bb header_text_color=\u00a0\u00bb#E85D6B\u00a0\u00bb header_font_size=\u00a0\u00bb60px\u00a0\u00bb custom_margin=\u00a0\u00bb11px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Consortium<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ admin_label=\u00a0\u00bbfirst text colored pill\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_enable_color=\u00a0\u00bboff\u00a0\u00bb custom_padding=\u00a0\u00bb0px||0px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb vertical_offset=\u00a0\u00bb-164px\u00a0\u00bb custom_margin=\u00a0\u00bb||-153px||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px||0px|false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb text_font_size=\u00a0\u00bb20px\u00a0\u00bb text_line_height=\u00a0\u00bb1.33em\u00a0\u00bb header_2_font=\u00a0\u00bbPoppins regular||||||||\u00a0\u00bb header_2_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_2_font_size=\u00a0\u00bb24px\u00a0\u00bb background_color=\u00a0\u00bb#048EA3″ max_width=\u00a0\u00bb635px\u00a0\u00bb module_alignment=\u00a0\u00bbleft\u00a0\u00bb custom_padding=\u00a0\u00bb60px|92px|60px|30px|true|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bboverflow:visible;\u00a0\u00bb custom_css_after=\u00a0\u00bbcontent:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:635px;\u00a0\u00bb border_radii=\u00a0\u00bboff||999px|999px|\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Cette section fournit une vue d’ensemble du consortium du projet ASCERTAIN, y compris des informations sur les partenaires du projet et leurs r\u00f4les et responsabilit\u00e9s respectifs.<\/p>\n

Nous sommes un consortium de partenaires de sept pays (Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie) qui collaborent ensemble.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_padding=\u00a0\u00bb8px||36px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_padding=\u00a0\u00bb|30px|40px|30px|false|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/logo-erasmus-universiteit.png\u00a0\u00bb title_text=\u00a0\u00bblogo-erasmus-universiteit\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Erasmus Universiteit Rotterdam<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

L’universit\u00e9 Erasmus de Rotterdam (EUR) est une universit\u00e9 situ\u00e9e \u00e0 Rotterdam, aux Pays-Bas, qui compte 3 700 membres du personnel acad\u00e9mique et 23 867 \u00e9tudiants. L’Erasmus School of Health Policy & Management (ESHPM) est une \u00e9cole de recherche et d’enseignement multidisciplinaire de l’universit\u00e9. L’un de ses d\u00e9partements, l’Institute for Medical Technology Assessment (iMTA), a jou\u00e9 un r\u00f4le cl\u00e9 dans la recherche sur l’\u00e9valuation des technologies m\u00e9dicales aux Pays-Bas, en Europe et dans le monde. L’institut a men\u00e9 plus de 600 projets de recherche sur les soins de sant\u00e9 parrain\u00e9s par d’importants organismes de financement tels que les gouvernements et les institutions li\u00e9es au gouvernement, la Commission europ\u00e9enne, l’OMS, les organisations de soins de sant\u00e9, les fondations caritatives et l’industrie pharmaceutique. <\/p>\n

R\u00f4le dans le projet :<\/strong> EUR est le coordinateur de ce projet et apporte son expertise en mati\u00e8re de tarification, de th\u00e9rapie g\u00e9nique et cellulaire et de remboursement.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#fbedec\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Comenius_University_Bratislava.svg\u00a0\u00bb title_text=\u00a0\u00bbUniversit\u00e9 Comenius_Bratislava\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_padding_phone=\u00a0\u00bb|0px|20px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbwidth:79.35% !important;\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb0px||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Comenius University in Bratislava (UNIBA)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

L’universit\u00e9 Comenius de Bratislava est un \u00e9tablissement de recherche qui g\u00e8re des centaines de projets de recherche nationaux et internationaux. Un repr\u00e9sentant de la facult\u00e9 de pharmacie de l’universit\u00e9 Comenius de Bratislava a \u00e9t\u00e9 membre du comit\u00e9 de remboursement des m\u00e9dicaments du minist\u00e8re slovaque de la sant\u00e9 au nom du fonds d’assurance maladie de l’Union. <\/p>\n

R\u00f4le dans le projet :<\/strong> L’UNIBA apporte au projet son expertise en mati\u00e8re de dispositifs m\u00e9dicaux et de remboursement.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ locked=\u00a0\u00bboff\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/wortbildmarke-goeg-RGB.png\u00a0\u00bb title_text=\u00a0\u00bbwortbildmarke-goeg-RGB\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00a0\u00bb200px\u00a0\u00bb custom_margin=\u00a0\u00bb5px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Gesundheit \u00d6sterreich GmbH (GOEG)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

L\u2019Institut national autrichien de sant\u00e9 publique (Gesundheit \u00d6sterreich GmbH) est l\u2019institutresponsable de la recherche et de la planification des soins de sant\u00e9 publique en Autriche. Il fait \u00e9galement office de centre national de comp\u00e9tence et de financement pour la promotion de la sant\u00e9 et la pr\u00e9vention et facilite la recherche dans le domaine des soins de sant\u00e9. GOEG est une soci\u00e9t\u00e9 publique \u00e0 responsabilit\u00e9 limit\u00e9e \u00e0 but non lucratif, enti\u00e8rement d\u00e9tenue par la R\u00e9publique d\u2019Autriche, repr\u00e9sent\u00e9e par le minist\u00e8re f\u00e9d\u00e9ral des affaires sociales, de la sant\u00e9, des soins et de la protection des consommateurs. <\/p>\n

R\u00f4le dans le projet:<\/strong> GOEG apporte son expertise en mati\u00e8re de tarification des m\u00e9dicaments, de politiques de tarification et de remboursement des produits pharmaceutiques et des dispositifs m\u00e9dicaux, ainsi qu\u2019en mati\u00e8re de recherche comparative sur les syst\u00e8mes pharmaceutiques. En raison de sa collaboration avec les d\u00e9cideurs politiques, GOEG contribue \u00e9galement au partage d\u2019informations et \u00e0 la collaboration entre les pays dans le cadre du projet. <\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bbrgba(57,60,132,0.15)\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0″][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/university-of-oslo.png\u00a0\u00bb title_text=\u00a0\u00bbuniversit\u00e9 d'oslo\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=\u00a0\u00bb5px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Universitetet i Oslo <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

L’Universitetet i Oslo est la plus grande et la plus ancienne universit\u00e9 de Norv\u00e8ge. Elle compte 27 700 \u00e9tudiants et 6 000 employ\u00e9s. L’universit\u00e9 se compose de cinq facult\u00e9s qui m\u00e8nent des recherches et dispensent un enseignement en th\u00e9ologie, droit, m\u00e9decine, sciences humaines, math\u00e9matiques et sciences naturelles, odontologie, sciences sociales et sciences humaines. Les activit\u00e9s principales de la facult\u00e9 de m\u00e9decine sont la recherche, l’enseignement, la diffusion et l’innovation pour le bien des patients et de la soci\u00e9t\u00e9. <\/p>\n

R\u00f4le dans le projet :<\/strong> L’UIO contribue aux cas d’utilisation des m\u00e9dicaments anticanc\u00e9reux de pr\u00e9cision et des dispositifs m\u00e9dicaux, et apporte son expertise en mati\u00e8re d’ETS, de mod\u00e9lisation math\u00e9matique de simulation, de d\u00e9finition des priorit\u00e9s et d’analyse des donn\u00e9es des registres.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/AIM-LOGO_png24.png\u00a0\u00bb title_text=\u00a0\u00bbAIM-LOGO_png24″ url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00a0\u00bb150px\u00a0\u00bb custom_margin=\u00a0\u00bb5px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

The International Association of Mutual Benefit Societies (AIM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

L’AIM est l’organisation fa\u00eeti\u00e8re internationale des f\u00e9d\u00e9rations de mutuelles de sant\u00e9 et des organismes d’assurance maladie l\u00e9gale et compl\u00e9mentaire.
Le travail de ses membres est bas\u00e9 sur la solidarit\u00e9, le travail sans but lucratif et la d\u00e9mocratie \u00e0 travers l’Europe, l’Am\u00e9rique latine, l’Afrique et le Moyen-Orient.
L’AIM plaide pour l’\u00e9galit\u00e9 d’acc\u00e8s \u00e0 la sant\u00e9 et aux soins, une tarification \u00e9quitable des m\u00e9dicaments, une num\u00e9risation au service des assur\u00e9s, l’int\u00e9gration de la sant\u00e9 dans toutes les politiques et une plus grande attention port\u00e9e \u00e0 la pr\u00e9vention.<\/p>\n

R\u00f4le dans le projet :<\/strong> L’algorithme innovant combinant le caract\u00e8re abordable et le soutien \u00e0 l’innovation sera la base du mod\u00e8le de tarification innovant d’ASCERTAIN.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bbrgba(133,184,189,0.3)\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/Logo-EHA-Black.png\u00a0\u00bb title_text=\u00a0\u00bbLogo EHA – Noir\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.0″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00a0\u00bb150px\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

European Hematology Association (EHA) <\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

L’EHA est une organisation non gouvernementale \u00e0 but non lucratif dont la mission est de promouvoir l’excellence dans les soins aux patients, la recherche et l’\u00e9ducation en h\u00e9matologie. L’EHA est la plus grande organisation europ\u00e9enne qui rassemble des professionnels de la sant\u00e9, des chercheurs et des scientifiques int\u00e9ress\u00e9s par l’h\u00e9matologie. L’EHA repr\u00e9sente l’h\u00e9matologie et les h\u00e9matologues dans l’ar\u00e8ne politique europ\u00e9enne afin d’am\u00e9liorer la r\u00e9glementation, d’accro\u00eetre la disponibilit\u00e9 et l’accessibilit\u00e9 des m\u00e9dicaments et d’harmoniser l’\u00e9ducation et la formation des h\u00e9matologues. <\/p>\n

R\u00f4le dans le projet :<\/strong> apporte son expertise en mati\u00e8re de tarification et de rentabilit\u00e9 dans le cadre du projet.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Chino.io-logo.png\u00a0\u00bb title_text=\u00a0\u00bbChino.io – logo\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Chino.io (CHINO)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Chino SRL est une soci\u00e9t\u00e9 italienne de cybers\u00e9curit\u00e9 et de technologie cloud fond\u00e9e en 2014 avec pour mission d’aider les d\u00e9veloppeurs d’applications de sant\u00e9 \u00e0 r\u00e9soudre les probl\u00e8mes de s\u00e9curit\u00e9 et de conformit\u00e9 aux lois sur la protection de la vie priv\u00e9e lorsqu’ils traitent des donn\u00e9es sensibles en mati\u00e8re de sant\u00e9 dans le cloud. Chino SRL a cr\u00e9\u00e9 une plateforme de d\u00e9veloppement de logiciels appel\u00e9e Chino.io. Cette plateforme offre aux d\u00e9veloppeurs un ensemble d’API pour stocker, partager et g\u00e9rer les donn\u00e9es de sant\u00e9 sensibles en toute s\u00e9curit\u00e9 et se conformer pleinement \u00e0 toutes les lois sur la protection des donn\u00e9es, y compris le GDPR, ePrivacy et HIPAA. <\/p>\n

R\u00f4le dans le projet :<\/strong> <\/span><\/strong>Gestion des donn\u00e9es et \u00e9thique dans le WP2.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#fbedec\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/MPE-Logo.png\u00a0\u00bb title_text=\u00a0\u00bbLogo du PPE\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00a0\u00bb100px\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Myeloma Patients Europe (MPE)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Myeloma Patients Europe (MPE) est une organisation qui regroupe des groupes de patients atteints de my\u00e9lome et d’amylose AL dans toute l’Europe. MPE compte actuellement 53 membres r\u00e9partis dans 33 pays. La mission de l’organisation est de fournir de l’\u00e9ducation, de l’information et du soutien aux groupes membres et de plaider aux niveaux europ\u00e9en, national et local pour la meilleure recherche possible et l’\u00e9galit\u00e9 d’acc\u00e8s aux traitements et aux soins. Pour atteindre ses objectifs, MPE travaille directement avec ses membres, les professionnels de la sant\u00e9, les autorit\u00e9s de remboursement, les r\u00e9gulateurs, les politiciens, les soci\u00e9t\u00e9s pharmaceutiques et les m\u00e9dias afin de s’assurer que toutes les parties prenantes collaborent \u00e0 l’am\u00e9lioration des r\u00e9sultats pour les patients et \u00e0 la r\u00e9duction des in\u00e9galit\u00e9s \u00e0 travers l’Europe. <\/p>\n

R\u00f4le dans le projet :<\/strong> engagement des patients, identification des besoins et des pr\u00e9f\u00e9rences des patients pour le d\u00e9veloppement des mod\u00e8les.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.27.4″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bbRGBA(255,255,255,0)\u00a0\u00bb custom_padding=\u00a0\u00bb45px||45px||true|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row column_structure=\u00a0\u00bb1_4,3_4″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb gutter_width=\u00a0\u00bb1″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ custom_padding=\u00a0\u00bb|25px|||false|false\u00a0\u00bb custom_css_main_element=\u00a0\u00bbwidth:20.65% !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/OptiMedis_RGB.svg\u00a0\u00bb title_text=\u00a0\u00bbOptiMedis_RGB\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb26b0c6d0-49a7-457d-8215-e0775d6dd853″ max_width_phone=\u00a0\u00bb130px\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00a0\u00bb3_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbf72966c0-c6ca-409f-a2c1-5e5bf3d89104″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ header_2_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_2_line_height=\u00a0\u00bb1.1em\u00a0\u00bb custom_margin=\u00a0\u00bb||22px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

OptiMedis AG (OM)<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.0″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

OptiMedis est une soci\u00e9t\u00e9 de gestion et d’analyse des donn\u00e9es de sant\u00e9 enregistr\u00e9e en Allemagne. Son activit\u00e9 principale consiste \u00e0 d\u00e9velopper et \u00e0 g\u00e9rer des syst\u00e8mes r\u00e9gionaux de prestation de soins int\u00e9gr\u00e9s avec des r\u00e9seaux de m\u00e9decins et d’autres prestataires. L’approche d’OptiMedis en mati\u00e8re de transformation des syst\u00e8mes de soins de sant\u00e9 a \u00e9t\u00e9 fr\u00e9quemment reconnue par l’UE, de nombreux projets de recherche de l’UE, le Commonwealth Fund, le Duke Margolis Centre for Health Policy, l’OMS, la Banque mondiale et d’autres. OptiMedis g\u00e8re trois syst\u00e8mes de prestation de soins int\u00e9gr\u00e9s en Allemagne, avec une population de plus de 120 000 personnes et impliquant plus de 150 prestataires de soins de sant\u00e9. OptiMedis est actuellement impliqu\u00e9 dans des projets comp\u00e9titifs de recherche et de mise en \u0153uvre d’un volume de plus de 10 millions d’euros. <\/p>\n

R\u00f4le dans le projet : <\/strong>Activit\u00e9s de diffusion et d’exploitation du projet, fabrication \u00e9cologique des technologies de la sant\u00e9.<\/p>\n

[\/et_pb_text][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/\u00a0\u00bb button_text=\u00a0\u00bbVoir l \u00e9quipe!\u00a0\u00bb button_alignment=\u00a0\u00bbleft\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bb934a713e-7600-4210-b519-38aa562ec140″ button_bg_color=\u00a0\u00bbRGBA(255,255,255,0)\u00a0\u00bb custom_padding_last_edited=\u00a0\u00bboff|phone\u00a0\u00bb button_font_last_edited=\u00a0\u00bboff|desktop\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb button_bg_enable_color__hover=\u00a0\u00bbon\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1″ module_id=\u00a0\u00bbcontact\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#86B8BD\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb16px||75px||false|false\u00a0\u00bb box_shadow_style=\u00a0\u00bbpreset7″ box_shadow_horizontal=\u00a0\u00bb0px\u00a0\u00bb box_shadow_vertical=\u00a0\u00bb-274px\u00a0\u00bb box_shadow_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_module=\u00a0\u00bb910″ saved_tabs=\u00a0\u00bball\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_font_size=\u00a0\u00bb36px\u00a0\u00bb custom_margin=\u00a0\u00bb14px||23px||false|false\u00a0\u00bb custom_margin_tablet=\u00a0\u00bb\u00a0\u00bb custom_margin_phone=\u00a0\u00bb||30px||false|false\u00a0\u00bb custom_margin_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb header_font_size_phone=\u00a0\u00bb24px\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Contact<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_font=\u00a0\u00bbPoppins regular||||||||\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84″ text_font_size=\u00a0\u00bb24px\u00a0\u00bb text_line_height=\u00a0\u00bb1.33em\u00a0\u00bb module_alignment=\u00a0\u00bbright\u00a0\u00bb custom_margin=\u00a0\u00bb||0px||false|false\u00a0\u00bb text_font_size_tablet=\u00a0\u00bb\u00a0\u00bb text_font_size_phone=\u00a0\u00bb18px\u00a0\u00bb text_font_size_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

N’h\u00e9sitez pas \u00e0 nous contacter si vous avez des questions ou des commentaires ! Nous vous r\u00e9pondrons dans les plus brefs d\u00e9lais. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00a0\u00bb1_3,1_3,1_3″ use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb module_class=\u00a0\u00bbtablet-three-cols\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb max_width_tablet=\u00a0\u00bb980px\u00a0\u00bb max_width_phone=\u00a0\u00bb500px\u00a0\u00bb max_width_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb custom_padding=\u00a0\u00bb0px|30px|0px|30px|false|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbdisplay:flex;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbdisplay:flex; flex-direction:column;\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_3″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbmargin-bottom:0;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbmargin-bottom:20px;\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png\u00a0\u00bb title_text=\u00a0\u00bbCarin_Uyl-de-Groot\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Pour les questions relatives \u00e0 la recherche :<\/p>\n

Carin Uyl-de Groot<\/strong>
Coordinatrice de projet<\/p>\n

Universit\u00e9 Erasmus de Rotterdam
uyl@eshpm.eur.nl<\/a>
T\u00e9l\u00e9phone : +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_3″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00a0\u00bb background_color=\u00a0\u00bb#393C84″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbmargin-bottom:0;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbmargin-bottom:20px;\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png\u00a0\u00bb title_text=\u00a0\u00bbMarcel-Langone\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Pour des questions g\u00e9n\u00e9rales sur le projet :<\/p>\n

Marcel Langone Marques<\/strong>
Chef de projet<\/p>\n

Universit\u00e9 Erasmus de Rotterdam
marcel.langonemarques@eur.nl<\/a>
T\u00e9l\u00e9phone : +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_3″ _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00a0\u00bb background_color=\u00a0\u00bb#048EA3″ global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png\u00a0\u00bb title_text=\u00a0\u00bbMon projet-1 (7)\u00a0\u00bb _builder_version=\u00a0\u00bb4.21.0″ _module_preset=\u00a0\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00a0\u00bb4.20.2″ _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n

Pour les communications :<\/p>\n

Lena Jessen<\/strong>
Chef de projet<\/p>\n

OptiMedis
l.jessen@optimedis.de<\/a>
T\u00e9l\u00e9phone : +49 40 226211490<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

ConsortiumCette section fournit une vue d’ensemble du consortium du projet ASCERTAIN, y compris des informations sur les partenaires du projet et leurs r\u00f4les et responsabilit\u00e9s respectifs. Nous sommes un consortium de partenaires de sept pays (Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie) qui collaborent ensemble.Erasmus Universiteit RotterdamL’universit\u00e9 Erasmus de Rotterdam (EUR) est une universit\u00e9 situ\u00e9e \u00e0 Rotterdam, aux Pays-Bas, qui compte 3 700 membres du personnel acad\u00e9mique et 23 867 \u00e9tudiants. L’Erasmus School of Health Policy & Management (ESHPM) est une \u00e9cole de recherche et d’enseignement multidisciplinaire de l’universit\u00e9. L’un de ses d\u00e9partements, l’Institute for Medical Technology Assessment (iMTA), a jou\u00e9 un r\u00f4le cl\u00e9 dans la recherche sur l’\u00e9valuation des technologies m\u00e9dicales aux Pays-Bas, en Europe et dans le monde. L’institut a men\u00e9 plus de 600 projets de recherche sur les soins de sant\u00e9 parrain\u00e9s par d’importants organismes de financement tels que les gouvernements et les institutions li\u00e9es au gouvernement, la Commission europ\u00e9enne, l’OMS, les organisations de soins de sant\u00e9, les fondations caritatives et l’industrie pharmaceutique. R\u00f4le dans le projet : EUR est le coordinateur de ce projet et apporte son expertise en mati\u00e8re de tarification, de th\u00e9rapie g\u00e9nique et cellulaire et de remboursement.Comenius University in Bratislava (UNIBA)L’universit\u00e9 Comenius […]<\/p>\n","protected":false},"author":1,"featured_media":2553,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-3534","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nConsortium - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"Le projet ASCERTAIN rassemble dix partenaires de sept pays : Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/fr\/consortium\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consortium\" \/>\n<meta property=\"og:description\" content=\"Le projet ASCERTAIN rassemble dix partenaires de sept pays : Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/fr\/consortium\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T13:56:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1254\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"23 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/\",\"name\":\"Consortium - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"datePublished\":\"2023-03-03T16:32:28+00:00\",\"dateModified\":\"2025-06-24T13:56:51+00:00\",\"description\":\"Le projet ASCERTAIN rassemble dix partenaires de sept pays : Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Foto_1093935162_iStock_Rawpixel.jpg\",\"width\":1254,\"height\":836},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/consortium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/startseite\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Consortium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Consortium - ASCERTAIN","description":"Le projet ASCERTAIN rassemble dix partenaires de sept pays : Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/fr\/consortium\/","og_locale":"fr_FR","og_type":"article","og_title":"Consortium","og_description":"Le projet ASCERTAIN rassemble dix partenaires de sept pays : Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie.","og_url":"https:\/\/www.access2meds.eu\/fr\/consortium\/","og_site_name":"ASCERTAIN","article_modified_time":"2025-06-24T13:56:51+00:00","og_image":[{"width":1254,"height":836,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"23 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/fr\/consortium\/","url":"https:\/\/www.access2meds.eu\/fr\/consortium\/","name":"Consortium - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/fr\/consortium\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/fr\/consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","datePublished":"2023-03-03T16:32:28+00:00","dateModified":"2025-06-24T13:56:51+00:00","description":"Le projet ASCERTAIN rassemble dix partenaires de sept pays : Autriche, Belgique, Pays-Bas, Slovaquie, Norv\u00e8ge, Allemagne et Italie.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/fr\/consortium\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/fr\/consortium\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.access2meds.eu\/fr\/consortium\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1093935162_iStock_Rawpixel.jpg","width":1254,"height":836},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/fr\/consortium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/fr\/startseite\/"},{"@type":"ListItem","position":2,"name":"Consortium"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages\/3534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/comments?post=3534"}],"version-history":[{"count":20,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages\/3534\/revisions"}],"predecessor-version":[{"id":4568,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages\/3534\/revisions\/4568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/media\/2553"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/media?parent=3534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}